Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule.

Yang Y, Xiao Y, Wu J.

Bull Math Biol. 2013 May;75(5):725-51. doi: 10.1007/s11538-013-9831-8. Epub 2013 Mar 28.

PMID:
23535904
2.

Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?

Smith RJ, Schwartz EJ.

Math Biosci. 2008 Apr;212(2):180-7. doi: 10.1016/j.mbs.2008.02.001. Epub 2008 Feb 20.

PMID:
18359048
5.
6.

Rates of HIV immune escape and reversion: implications for vaccination.

Davenport MP, Loh L, Petravic J, Kent SJ.

Trends Microbiol. 2008 Dec;16(12):561-6. doi: 10.1016/j.tim.2008.09.001. Epub 2008 Oct 27.

PMID:
18964018
7.

Optimal HIV treatment by maximising immune response.

Culshaw RV, Ruan S, Spiteri RJ.

J Math Biol. 2004 May;48(5):545-62. Epub 2003 Oct 27.

PMID:
15133623
8.
9.

Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).

Launay O, Surenaud M, Desaint C, Ben Hamouda N, Pialoux G, Bonnet B, Poizot-Martin I, Gonzales G, Cuzin L, Bourgault-Villada I, Lévy Y, Choppin J, Durier C.

Vaccine. 2013 Sep 13;31(40):4406-15. doi: 10.1016/j.vaccine.2013.06.102. Epub 2013 Jul 11.

PMID:
23850610
10.

mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.

Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN.

AIDS. 2012 Feb 20;26(4):F1-12. doi: 10.1097/QAD.0b013e32834f33e8.

PMID:
22156965
11.

Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.

Cristillo AD, Wang S, Caskey MS, Unangst T, Hocker L, He L, Hudacik L, Whitney S, Keen T, Chou TH, Shen S, Joshi S, Kalyanaraman VS, Nair B, Markham P, Lu S, Pal R.

Virology. 2006 Mar 1;346(1):151-68. Epub 2005 Dec 2.

12.

Mechanism of HIV persistence: implications for vaccines and therapy.

Bremermann HJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Aug 15;9(5):459-83. Review.

PMID:
7627623
13.

An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers.

Van Braeckel E, Bourguignon P, Koutsoukos M, Clement F, Janssens M, Carletti I, Collard A, Demoitié MA, Voss G, Leroux-Roels G, McNally L.

Clin Infect Dis. 2011 Feb 15;52(4):522-31. doi: 10.1093/cid/ciq160. Epub 2011 Jan 5.

14.

Induction of strong anti-HIV cellular immunity by a combination of Clostridium perfringens expressing HIV gag and virus like particles.

Pegu P, Helmus R, Gupta P, Tarwater P, Caruso L, Shen C, Ross T, Chen Y.

Curr HIV Res. 2011 Dec 1;9(8):613-22.

PMID:
22211658
15.

Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.

Promkhatkaew D, Matsuo K, Pinyosukhee N, Thongdeejaroen W, Leang-Aramgul P, Sawanpanyalert P, Warachit P.

Southeast Asian J Trop Med Public Health. 2009 Mar;40(2):273-81.

PMID:
19323012
16.

Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene.

Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, Freed DC, Wilson KA, Dubey S, Zhu DM, Nawrocki D, Mach H, Troutman R, Isopi L, Williams D, Hurni W, Xu Z, Smith JG, Wang S, Liu X, Guan L, Long R, Trigona W, Heidecker GJ, Perry HC, Persaud N, Toner TJ, Su Q, Liang X, Youil R, Chastain M, Bett AJ, Volkin DB, Emini EA, Shiver JW.

J Virol. 2003 Jun;77(11):6305-13.

17.

The dual role of CD4 T helper cells in the infection dynamics of HIV and their importance for vaccination.

Altes HK, Wodarz D, Jansen VA.

J Theor Biol. 2002 Feb 21;214(4):633-46.

PMID:
11851372
18.

HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals.

Musey L, Ding Y, Elizaga M, Ha R, Celum C, McElrath MJ.

J Immunol. 2003 Jul 15;171(2):1094-101.

19.
Items per page

Supplemental Content

Write to the Help Desk